DiaSorin S.p.A. stock (IT0003497168): Q1 2026 earnings and buyback activity in focus

DiaSorin S.p.A. reports lower Q1 2026 earnings but confirms its 2026 guidance, while the company continues to buy back its own shares.

DiaSorin S.p.A. has reported its first?quarter 2026 results, showing lower sales and net profit versus the prior?year period but confirming its full?year 2026 guidance, according to a company announcement on May 8, 2026.MarketScreener as of May 08, 2026

For the three months ended March 31, 2026, DiaSorin recorded sales of about EUR 287 million, down from the prior?year quarter, with net profit at EUR 38 million compared with EUR 52 million in Q1 2025.MarketScreener as of May 08, 2026

Management attributed the softer performance mainly to a weaker flu season, which reduced demand for molecular diagnostic tests, a trend also noted by competitors in the diagnostics sector.MarketScreener as of May 08, 2026

Despite the lower Q1 figures, DiaSorin reiterated its 2026 guidance, signaling confidence in a recovery in the second half of the year and continued growth in its core diagnostic franchises.MarketScreener as of May 08, 2026

On the capital?allocation front, DiaSorin announced that it acquired more than 330,000 of its own ordinary shares between May 4 and May 8, 2026, at an average price of about EUR 61.79 per share, for a total consideration of roughly EUR 20.5 million.MarketScreener as of May 08, 2026

Following these purchases, DiaSorin holds about 6.1 million treasury shares, representing approximately 11% of its share capital, which gives the company flexibility for future capital?management actions.MarketScreener as of May 08, 2026

On the Milan Stock Exchange, DiaSorin’s shares closed around EUR 63.20 on May 8, 2026, down about 1.6% on the day, reflecting investor reaction to the mixed Q1 update and ongoing macro and seasonal pressures in diagnostics.MarketScreener as of May 08, 2026

As of: 09.05.2026

By the editorial team – specialized in equity coverage.

At a glance

• Name: DiaSorin S.p.A.
• Sector/industry: Healthcare diagnostics / in vitro diagnostics
• Headquarters/country: Italy
• Core markets: Europe, North America, Latin America, Asia?Pacific
• Key revenue drivers: Infectious disease testing, autoimmune diagnostics, endocrinology, molecular diagnostics platforms
• Home exchange/listing venue: Borsa Italiana (Milan), ticker DIAS
• Trading currency: EUR

DiaSorin S.p.A.: core business model

DiaSorin S.p.A. is an Italian diagnostics company focused on in vitro tests for infectious diseases, autoimmune disorders, endocrinology and other specialty areas, serving hospitals, reference laboratories and public?health institutions worldwide.DiaSorin Newsroom as of May 08, 2026

The company generates revenue through the sale of proprietary test kits and reagents, as well as through its installed base of automated diagnostic instruments, which create recurring consumables demand and service contracts.DiaSorin Newsroom as of May 08, 2026

DiaSorin’s business model emphasizes innovation in immunoassay and molecular technologies, with a strategy to expand its menu of tests and strengthen its presence in emerging markets and in high?growth segments such as autoimmune and infectious?disease diagnostics.DiaSorin Newsroom as of May 08, 2026

Main revenue and product drivers for DiaSorin S.p.A.

Key revenue drivers for DiaSorin include its infectious?disease portfolio, particularly tests for hepatitis, HIV, syphilis and other sexually transmitted infections, which benefit from global screening programs and public?health initiatives.DiaSorin Newsroom as of May 08, 2026

The company’s autoimmune diagnostics segment, covering tests for conditions such as celiac disease and other autoimmune disorders, has also contributed to growth, supported by increasing awareness and diagnostic rates in both developed and developing markets.DiaSorin Newsroom as of May 08, 2026

DiaSorin’s molecular diagnostics platforms, including its Luminex?based and other molecular systems, provide a growth avenue in areas such as respiratory infections and other infectious?disease panels, although recent performance has been affected by seasonal flu patterns and lower testing volumes.MarketScreener as of May 08, 2026

Conclusion

DiaSorin S.p.A. faces near?term headwinds from softer seasonal demand in infectious?disease testing, which has weighed on Q1 2026 earnings and contributed to a modest share?price decline.MarketScreener as of May 08, 2026

At the same time, the company continues to invest in its product portfolio and has signaled ongoing capital?return discipline through share buybacks, which may support shareholder value over the medium term.MarketScreener as of May 08, 2026

For US investors, DiaSorin offers exposure to the global diagnostics sector via its Milan listing and international revenue base, but the stock’s performance will remain sensitive to seasonal testing patterns, competitive dynamics and broader healthcare?spending trends.DiaSorin Newsroom as of May 08, 2026

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.